

Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. *Blood Adv.* 2017;1(14):933-946.

On page 933 of the 13 June 2017 issue, the affiliation of author Mark J. Axelrod was incorrect. The corrected author list and affiliation line are shown below. The error has been corrected in the published article.

Kallesh D. Jayappa,^{1,2} Craig A. Portell,^{3,4} Vicki L. Gordon,^{1,2} Brian J. Capaldo,⁵ Stefan Bekiranov,⁵ Mark J. Axelrod,^{1,4} L. Kyle Brett,⁶ Julia D. Wulfkuhle,⁷ Rosa I. Gallagher,⁷ Emanuel F. Petricoin,⁷ Timothy P. Bender,^{1,2} Michael E. Williams,^{3,4} and Michael J. Weber^{1,2,4}

¹Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA; ²Beirne B. Carter Center for Immunology Research, Charlottesville, VA; ³Division of Hematology/Oncology, School of Medicine, ⁴Cancer Center, and ⁵Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA; ⁶Medical Oncology, Utica Park Clinic, Tulsa, OK; and ⁷Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA

DOI 10.1182/bloodadvances.2017011148

© 2017 by The American Society of Hematology